Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 502 entries
Sorted by: Best Match Show Resources per page
ON THE MUTAGENIC EFFECT OF ALKYLATING AGENTS.

Proceedings of the National Academy of Sciences of the United States of America

Bautz E, Freese E.
PMID: 16590785
Proc Natl Acad Sci U S A. 1960 Dec;46(12):1585-94. doi: 10.1073/pnas.46.12.1585.

No abstract available.

Cite
Bautz E, Freese E. ON THE MUTAGENIC EFFECT OF ALKYLATING AGENTS. Proc Natl Acad Sci U S A. 1960;46(12):1585-94doi: 10.1073/pnas.46.12.1585.
Bautz, E., & Freese, E. (1960). ON THE MUTAGENIC EFFECT OF ALKYLATING AGENTS. Proceedings of the National Academy of Sciences of the United States of America, 46(12), 1585-94. https://doi.org/10.1073/pnas.46.12.1585
Bautz, E, and Freese, E. "ON THE MUTAGENIC EFFECT OF ALKYLATING AGENTS." Proceedings of the National Academy of Sciences of the United States of America vol. 46,12 (1960): 1585-94. doi: https://doi.org/10.1073/pnas.46.12.1585
Bautz E, Freese E. ON THE MUTAGENIC EFFECT OF ALKYLATING AGENTS. Proc Natl Acad Sci U S A. 1960 Dec;46(12):1585-94. doi: 10.1073/pnas.46.12.1585. PMID: 16590785; PMCID: PMC223084.
Copy Download .nbib Format: NLM
Is malignancy a major concern in rheumatoid arthritis patients?.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

Cash JM, Klippel JH.
PMID: 19077936
J Clin Rheumatol. 1995 Feb;1(1):14-22. doi: 10.1097/00124743-199502000-00005.

There are several major issues related to malignancy that are of importance to the practicing clinician caring for patients with rheumatoid arthritis. Although it has been clearly established that rheumatoid arthritis is associated with an increased risk of hematologic...

Cite
Cash JM, Klippel JH. Is malignancy a major concern in rheumatoid arthritis patients?. J Clin Rheumatol. 1995;1(1):14-22doi: 10.1097/00124743-199502000-00005.
Cash, J. M., & Klippel, J. H. (1995). Is malignancy a major concern in rheumatoid arthritis patients?. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 1(1), 14-22. https://doi.org/10.1097/00124743-199502000-00005
Cash, J M, and Klippel, J H. "Is malignancy a major concern in rheumatoid arthritis patients?." Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases vol. 1,1 (1995): 14-22. doi: https://doi.org/10.1097/00124743-199502000-00005
Cash JM, Klippel JH. Is malignancy a major concern in rheumatoid arthritis patients?. J Clin Rheumatol. 1995 Feb;1(1):14-22. doi: 10.1097/00124743-199502000-00005. PMID: 19077936.
Copy Download .nbib Format: NLM
Leukemia risk after adjuvant treatment of early breast cancer.

Women's health (London, England)

Balduzzi A, Castiglione-Gertsch M.
PMID: 19803948
Womens Health (Lond). 2005 Jul;1(1):73-85. doi: 10.2217/17455057.1.1.73.

Modern cancer treatment has substantially increased the survival and curability of patients with various malignancies. Therefore, favorable prognosis mandates for the evaluation of long-term complications of treatment. Since the late 1970s, adjuvant combination chemotherapy for operable breast cancer has...

Cite
Balduzzi A, Castiglione-Gertsch M. Leukemia risk after adjuvant treatment of early breast cancer. Womens Health (Lond). 2005;1(1):73-85doi: 10.2217/17455057.1.1.73.
Balduzzi, A., & Castiglione-Gertsch, M. (2005). Leukemia risk after adjuvant treatment of early breast cancer. Women's health (London, England), 1(1), 73-85. https://doi.org/10.2217/17455057.1.1.73
Balduzzi, Alessandra, and Castiglione-Gertsch, Monica. "Leukemia risk after adjuvant treatment of early breast cancer." Women's health (London, England) vol. 1,1 (2005): 73-85. doi: https://doi.org/10.2217/17455057.1.1.73
Balduzzi A, Castiglione-Gertsch M. Leukemia risk after adjuvant treatment of early breast cancer. Womens Health (Lond). 2005 Jul;1(1):73-85. doi: 10.2217/17455057.1.1.73. PMID: 19803948.
Copy Download .nbib Format: NLM
Development of a Novel Fluorescence Assay Based on the Use of the Thrombin-Binding Aptamer for the Detection of O-Alkylguanine-DNA Alkyltransferase Activity.

Journal of nucleic acids

Tintoré M, Aviñó A, Ruiz FM, Eritja R, Fàbrega C.
PMID: 20936180
J Nucleic Acids. 2010 Sep 14;2010. doi: 10.4061/2010/632041.

Human O(6)-alkylguanine-DNA alkyltransferase (hAGT) is a DNA repair protein that reverses the effects of alkylating agents by removing DNA adducts from the O(6) position of guanine. Here, we developed a real-time fluorescence hAGT activity assay that is based on...

Cite
Tintoré M, Aviñó A, Ruiz FM, et al. Development of a Novel Fluorescence Assay Based on the Use of the Thrombin-Binding Aptamer for the Detection of O-Alkylguanine-DNA Alkyltransferase Activity. J Nucleic Acids. 2010;2010doi: 10.4061/2010/632041.
Tintoré, M., Aviñó, A., Ruiz, F. M., Eritja, R., & Fàbrega, C. (2010). Development of a Novel Fluorescence Assay Based on the Use of the Thrombin-Binding Aptamer for the Detection of O-Alkylguanine-DNA Alkyltransferase Activity. Journal of nucleic acids, 2010. https://doi.org/10.4061/2010/632041
Tintoré, Maria, et al. "Development of a Novel Fluorescence Assay Based on the Use of the Thrombin-Binding Aptamer for the Detection of O-Alkylguanine-DNA Alkyltransferase Activity." Journal of nucleic acids vol. 2010 (2010). doi: https://doi.org/10.4061/2010/632041
Tintoré M, Aviñó A, Ruiz FM, Eritja R, Fàbrega C. Development of a Novel Fluorescence Assay Based on the Use of the Thrombin-Binding Aptamer for the Detection of O-Alkylguanine-DNA Alkyltransferase Activity. J Nucleic Acids. 2010 Sep 14;2010. doi: 10.4061/2010/632041. PMID: 20936180; PMCID: PMC2946612.
Copy Download .nbib Format: NLM
Alteration in the capacities of carcinogen metabolizing system of mouse-livers during pretreatment with various antineoplastic agents.

Oncology reports

Mostafa M, Chalvardjian K, Lami H, Badawi A, Hamzah R.
PMID: 21607420
Oncol Rep. 1994 May;1(3):651-6. doi: 10.3892/or.1.3.651.

The effect of treatment with antineoplastic drugs on the modification of the carcinog en-metabolizing capacity was studied in mice liver microsomes at different durations as a single and as a repeated dose treatment. It is generally demonstrated that there...

Cite
Mostafa M, Chalvardjian K, Lami H, et al. Alteration in the capacities of carcinogen metabolizing system of mouse-livers during pretreatment with various antineoplastic agents. Oncol Rep. 1994;1(3):651-6doi: 10.3892/or.1.3.651.
Mostafa, M., Chalvardjian, K., Lami, H., Badawi, A., & Hamzah, R. (1994). Alteration in the capacities of carcinogen metabolizing system of mouse-livers during pretreatment with various antineoplastic agents. Oncology reports, 1(3), 651-6. https://doi.org/10.3892/or.1.3.651
Mostafa, M, et al. "Alteration in the capacities of carcinogen metabolizing system of mouse-livers during pretreatment with various antineoplastic agents." Oncology reports vol. 1,3 (1994): 651-6. doi: https://doi.org/10.3892/or.1.3.651
Mostafa M, Chalvardjian K, Lami H, Badawi A, Hamzah R. Alteration in the capacities of carcinogen metabolizing system of mouse-livers during pretreatment with various antineoplastic agents. Oncol Rep. 1994 May;1(3):651-6. doi: 10.3892/or.1.3.651. PMID: 21607420.
Copy Download .nbib Format: NLM
Therapy related acute myeloid leukemia with t(10:16): a rare entity.

Hematology reports

Uppal GK, Leighton J, Da Costa D, Czulewicz A, Palazzo IE.
PMID: 22593815
Hematol Rep. 2011 Oct 19;3(3):e23. doi: 10.4081/hr.2011.e23. Epub 2011 Dec 15.

Treatment related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) are well known complications after chemotherapy for various hematologic and non-hematologic malignancies. Alkylating agents and Topoisomerase inhibitors are most widely studied in this regard. There is growing concern about...

Cite
Uppal GK, Leighton J, Da Costa D, et al. Therapy related acute myeloid leukemia with t(10:16): a rare entity. Hematol Rep. 2011;3(3):e23doi: 10.4081/hr.2011.e23.
Uppal, G. K., Leighton, J., Da Costa, D., Czulewicz, A., & Palazzo, I. E. (2011). Therapy related acute myeloid leukemia with t(10:16): a rare entity. Hematology reports, 3(3), e23. https://doi.org/10.4081/hr.2011.e23
Uppal, Guldeep K, et al. "Therapy related acute myeloid leukemia with t(10:16): a rare entity." Hematology reports vol. 3,3 (2011): e23. doi: https://doi.org/10.4081/hr.2011.e23
Uppal GK, Leighton J, Da Costa D, Czulewicz A, Palazzo IE. Therapy related acute myeloid leukemia with t(10:16): a rare entity. Hematol Rep. 2011 Oct 19;3(3):e23. doi: 10.4081/hr.2011.e23. Epub 2011 Dec 15. PMID: 22593815; PMCID: PMC3269801.
Copy Download .nbib Format: NLM
A novel acid-catalyzed C5-alkylation of oxindoles using alcohols.

Organic & biomolecular chemistry

Reddy CR, Jithender E, Krishna G, Reddy GV, Jagadeesh B.
PMID: 21472162
Org Biomol Chem. 2011 May 21;9(10):3940-7. doi: 10.1039/c0ob01144d. Epub 2011 Apr 06.

A novel C5-alkylation of oxindoles using alcohols as alkylating agents under acid catalysis is described for the first time. The reactions of various benzylic, allylic and propargylic alcohols are studied to obtain the corresponding 5-substituted oxindoles in good yields.

Cite
Reddy CR, Jithender E, Krishna G, et al. A novel acid-catalyzed C5-alkylation of oxindoles using alcohols. Org Biomol Chem. 2011;9(10):3940-7doi: 10.1039/c0ob01144d.
Reddy, C. R., Jithender, E., Krishna, G., Reddy, G. V., & Jagadeesh, B. (2011). A novel acid-catalyzed C5-alkylation of oxindoles using alcohols. Organic & biomolecular chemistry, 9(10), 3940-7. https://doi.org/10.1039/c0ob01144d
Reddy, Chada Raji, et al. "A novel acid-catalyzed C5-alkylation of oxindoles using alcohols." Organic & biomolecular chemistry vol. 9,10 (2011): 3940-7. doi: https://doi.org/10.1039/c0ob01144d
Reddy CR, Jithender E, Krishna G, Reddy GV, Jagadeesh B. A novel acid-catalyzed C5-alkylation of oxindoles using alcohols. Org Biomol Chem. 2011 May 21;9(10):3940-7. doi: 10.1039/c0ob01144d. Epub 2011 Apr 06. PMID: 21472162.
Copy Download .nbib Format: NLM
Correlation of acute lethal potency with in vitro cytotoxicity.

Toxicology in vitro : an international journal published in association with BIBRA

Fry JR, Garle MJ, Hammond AH, Hatfield A.
PMID: 20837412
Toxicol In Vitro. 1990;4(3):175-8. doi: 10.1016/0887-2333(90)90018-o.

The in vitro cytotoxicity (measured as ID(50) value) of 27 compounds believed to act by interference with cell basal functions/structures has been determined and compared with their acute lethal toxicity (measured as oral and ip LD(50) values) using a...

Cite
Fry JR, Garle MJ, Hammond AH, et al. Correlation of acute lethal potency with in vitro cytotoxicity. Toxicol In Vitro. 1990;4(3):175-8doi: 10.1016/0887-2333(90)90018-o.
Fry, J. R., Garle, M. J., Hammond, A. H., & Hatfield, A. (1990). Correlation of acute lethal potency with in vitro cytotoxicity. Toxicology in vitro : an international journal published in association with BIBRA, 4(3), 175-8. https://doi.org/10.1016/0887-2333(90)90018-o
Fry, J R, et al. "Correlation of acute lethal potency with in vitro cytotoxicity." Toxicology in vitro : an international journal published in association with BIBRA vol. 4,3 (1990): 175-8. doi: https://doi.org/10.1016/0887-2333(90)90018-o
Fry JR, Garle MJ, Hammond AH, Hatfield A. Correlation of acute lethal potency with in vitro cytotoxicity. Toxicol In Vitro. 1990;4(3):175-8. doi: 10.1016/0887-2333(90)90018-o. PMID: 20837412.
Copy Download .nbib Format: NLM
Is bendamustine an ideal partner for rituximab in the management of relapsed chronic lymphocytic leukemia? Results of a multicenter Phase II trial.

Expert review of hematology

Montillo M.
PMID: 22272704
Expert Rev Hematol. 2012 Feb;5(1):43-6. doi: 10.1586/ehm.11.75.

First-line chemoimmunotherapy approaches offer prolonged disease-free survival in patients with chronic lymphocytic leukemia (CLL). Despite the improved results with purine analogs ± cyclophosphamide and rituximab (FCR) the disease remains incurable, and patients with CLL are destined to relapse after...

Cite
Montillo M. Is bendamustine an ideal partner for rituximab in the management of relapsed chronic lymphocytic leukemia? Results of a multicenter Phase II trial. Expert Rev Hematol. 2012;5(1):43-6doi: 10.1586/ehm.11.75.
Montillo, M. (2012). Is bendamustine an ideal partner for rituximab in the management of relapsed chronic lymphocytic leukemia? Results of a multicenter Phase II trial. Expert review of hematology, 5(1), 43-6. https://doi.org/10.1586/ehm.11.75
Montillo, Marco. "Is bendamustine an ideal partner for rituximab in the management of relapsed chronic lymphocytic leukemia? Results of a multicenter Phase II trial." Expert review of hematology vol. 5,1 (2012): 43-6. doi: https://doi.org/10.1586/ehm.11.75
Montillo M. Is bendamustine an ideal partner for rituximab in the management of relapsed chronic lymphocytic leukemia? Results of a multicenter Phase II trial. Expert Rev Hematol. 2012 Feb;5(1):43-6. doi: 10.1586/ehm.11.75. PMID: 22272704.
Copy Download .nbib Format: NLM
Idelalisib for the treatment of chronic lymphocytic leukemia.

ISRN oncology

Khan M, Saif A, Sandler S, Mirrakhimov AE.
PMID: 25093123
ISRN Oncol. 2014 Apr 01;2014:931858. doi: 10.1155/2014/931858. eCollection 2014.

Chronic lymphocytic leukemia is the most common leukemia in the United States. It is a slowly progressive disease, with an 82% five-year survival rate. The treatment strategies are highly individualized with patients in the early and stable stages typically...

Cite
Khan M, Saif A, Sandler S, et al. Idelalisib for the treatment of chronic lymphocytic leukemia. ISRN Oncol. 2014;2014:931858doi: 10.1155/2014/931858.
Khan, M., Saif, A., Sandler, S., & Mirrakhimov, A. E. (2014). Idelalisib for the treatment of chronic lymphocytic leukemia. ISRN oncology, 2014931858. https://doi.org/10.1155/2014/931858
Khan, Maliha, et al. "Idelalisib for the treatment of chronic lymphocytic leukemia." ISRN oncology vol. 2014 (2014): 931858. doi: https://doi.org/10.1155/2014/931858
Khan M, Saif A, Sandler S, Mirrakhimov AE. Idelalisib for the treatment of chronic lymphocytic leukemia. ISRN Oncol. 2014 Apr 01;2014:931858. doi: 10.1155/2014/931858. eCollection 2014. PMID: 25093123; PMCID: PMC4003830.
Copy Download .nbib Format: NLM
Expression of .

Journal of cancer therapy

Ishiguro K, Shyam K, Penketh PG, Baumann RP, Sartorelli AC, Rutherford TJ, Ratner ES.
PMID: 23946891
J Cancer Ther. 2013 Jun;4(4):919-931. doi: 10.4236/jct.2013.44103.

The tumor selectivity of alkylating agents that produce guanine

Cite
Ishiguro K, Shyam K, Penketh PG, et al. Expression of . J Cancer Ther. 2013;4(4):919-931doi: 10.4236/jct.2013.44103.
Ishiguro, K., Shyam, K., Penketh, P. G., Baumann, R. P., Sartorelli, A. C., Rutherford, T. J., & Ratner, E. S. (2013). Expression of . Journal of cancer therapy, 4(4), 919-931. https://doi.org/10.4236/jct.2013.44103
Ishiguro, Kimiko, et al. "Expression of ." Journal of cancer therapy vol. 4,4 (2013): 919-931. doi: https://doi.org/10.4236/jct.2013.44103
Ishiguro K, Shyam K, Penketh PG, Baumann RP, Sartorelli AC, Rutherford TJ, Ratner ES. Expression of . J Cancer Ther. 2013 Jun;4(4):919-931. doi: 10.4236/jct.2013.44103. PMID: 23946891; PMCID: PMC3740405.
Copy Download .nbib Format: NLM
Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US Population.

Sarcoma

Duh MS, Hackshaw MD, Ivanova JI, Kruse G, Miller LA, Lefebvre P, Karner P, Wong B.
PMID: 24453570
Sarcoma. 2013;2013:947413. doi: 10.1155/2013/947413. Epub 2013 Dec 23.

Background. The most common chemotherapies in metastatic soft tissue sarcoma (mSTS) require intravenous (IV) administration. This often requires patients to make multiple outpatient visits per chemotherapy cycle, possibly impeding patients' daily activities and increasing caregiver burden and medical costs....

Cite
Duh MS, Hackshaw MD, Ivanova JI, et al. Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US Population. Sarcoma. 2013;2013:947413doi: 10.1155/2013/947413.
Duh, M. S., Hackshaw, M. D., Ivanova, J. I., Kruse, G., Miller, L. A., Lefebvre, P., Karner, P., & Wong, B. (2013). Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US Population. Sarcoma, 2013947413. https://doi.org/10.1155/2013/947413
Duh, Mei Sheng, et al. "Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US Population." Sarcoma vol. 2013 (2013): 947413. doi: https://doi.org/10.1155/2013/947413
Duh MS, Hackshaw MD, Ivanova JI, Kruse G, Miller LA, Lefebvre P, Karner P, Wong B. Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US Population. Sarcoma. 2013;2013:947413. doi: 10.1155/2013/947413. Epub 2013 Dec 23. PMID: 24453570; PMCID: PMC3884837.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 502 entries